Mei Zhou

Mei Zhou

Auto-generated profile, based on publicly available information

Mei Zhou

Department of Radiation Medicine, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LXLijuan Xiong
Lijuan Xiong
QLQian Li
Qian Li
XCXiongjing Cao
Xiongjing Cao
HXHuangguo Xiong
Huangguo Xiong
MHMing Huang
Ming Huang
YHYu Hu
Yu Hu
This study aimed to evaluate the recovery of functional fitness, lung function, and immune function in healthcare workers (HCWs) with nonsevere and severe COVID-19 at 13 months after discharge from the hospital. The participants of “Rehabilitation Care Project for Medical Staff Infected with COVID-19” underwent a functional fitness test (muscle strength, flexibility, and agility/dynamic balance), lung function test, and immune function test (including cytokines and lymphocyte subsets) at 13 months after discharge. The project included 779 HCWs (316 nonsevere COVID-19 and 463 severe COVID-19). This study found that 29.1% (130/446) of the HCWs have not yet recovered their functional fitness. The most affected lung function indicator was lung perfusion capacity (34% with diffusion capacity for carbon monoxide-single breath <80%). The increase of interleukin-6 (64/534, 12.0%) and natural killer cells (44/534, 8.2%) and the decrease of CD3+ T cells (58/534, 10.9%) and CD4+ T cells (26/534, 4.9%) still existed at 13 months after discharge. No significant difference was found in the HCWs with nonsevere and severe COVID-19 regarding recovery of functional fitness, lung function, and immune function at 13 months after discharge. The majority of Chinese HCWs with COVID-19 had recovered their functional fitness, lung function, and immune function, and the recovery status in HCWs with severe COVID-19 is no worse than that in HCWs with nonsevere COVID-19 at 13 months after discharge from the hospital.

1 August 2022 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
PLPan Luo
Pan Luo
WLWei Liu
Wei Liu
MZMei Zhou
Mei Zhou
YLYouwei Li
Youwei Li
kuan linkuan lin
kuan lin
Background: Cerebrovascular lesions could induce affective disorders; however, the depression- and anxiety-related symptoms caused by chronic cerebral hypoperfusion (CCH) and the roles of different hyperpolarization-activated cyclic nucleotide-gated (HCN), KCNQ and G proteincoupled inwardly rectifying potassium (GirK) channel subunits in these pathological processes have been poorly elucidated so far. Objective: To investigate the behavioral change and the alteration of HCN, KCNQ, and GirK subunits in amygdale rats suffering from CCH. Methods: Permanent bilateral occlusion of the common carotid arteries was used to induce CCH. Anxiety and depression levels were assessed by the elevated plus maze test, sucrose preference test and forced swimming test to classify rats as highly anxious or depressive ‘susceptibility’ vs. ‘unsusceptibility’. The expression of brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor B (TrKB), HCN1/2, KCNQ2/3, and GirK1/2/3 were quantified by Western blotting. Results: The main emotional change caused by 4 weeks of CCH is likely to be anxiety-like behavior (50%), accompanied by a down-regulation of BDNF and TrKB expression in amygdale. The increase of HCN1 and decrease of KCNQ3 expression in amygdale may be factors to blame for anxiety- like symptom caused by CCH, and the increase of KCNQ2 and Girk1 expression in amygdale may play a role in resilience to the anxiety induced by CCH. Conclusion: The different subunits of HCN, KCNQ and GirK channels in amygdale may contribute to distinct response to aversive stimuli or stress induced by CCH that evokes divergent influences on anxiety-like behavior in rats.

1 January 2020 in Signa Vitae
Verified
Journal Article
Closed access
MZMei Zhou
Mei Zhou
XXXianzhi Xiong
Xianzhi Xiong
The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, is causing a pandemic. With an increased understanding of the disease, the diagnosis and treatment guidelines are being updated and improved. In addition to nucleic acid detection, antibody detection kits are also being developed and approved. A medical worker suspected of having COVID-19 in our hospital had fatigue and loss of appetite and pulmonary infection indicated by CT, but the nucleic acid test was negative three times. Finally, she was confirmed to have COVID-19 by a serological antibody test. After rest and oral antiviral treatment, she recovered and returned to work. This is a case report that focuses on suspected mild patients who tested negative for nucleic acids. Such a group of patients had to choose home isolation treatment during the outbreak. The majority of them did not make a definitive diagnosis or rule out COVID-19 by the time they recovered. The antibody test is of great significance to identify infected patients with multiple negative nucleic acid tests. It can complement nucleic acid testing to enhance diagnostic efficiency. We have reviewed the literature and realized that further validation and standardization of serological tests are needed for more mature application of antibody tests to clinical diagnosis and vaccine development.